Positive Results for Psoriasis Patients Treated with Clarify Home Light Therapy System Published in Dermatology Online Journal

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Clarify Medical today announced the publication of clinical study results using the Clarify Home Light Therapy System to treat patients with plaque psoriasis. The study demonstrated treatment efficacy, adherence, safety, and patient satisfaction using the novel connected home phototherapy system.

Eight adult patients with stable plaque psoriasis who were previously unresponsive to topical therapies completed a 10-week study using the Clarify System as a monotherapy. All patients that completed the study experienced improvement in the treated lesions, with a mean improvement of 57% in PSI (p<0.0001 compared to baseline and p<0.0002 compared to the control lesions). Control lesions did not significantly change over the treatment period (p=0.1411). At the conclusion of the study, when restrictions on combination therapy were lifted and topical corticosteroids were reintroduced, all patients reported 100% clearance within an additional 3 weeks. No adverse events or system functionality issues were reported. For those that completed the study, patient treatment adherence to the therapy was 96% and the Clarify System received five-star satisfaction scores from 100% of patients.

“This study shows strong clinical results with at-home based Narrow Band UVB phototherapy using the Clarify Medical Home Light Therapy System,” said Lawrence D. Eichenfield, M.D., Professor of Dermatology and Pediatrics and Chief of Pediatric Dermatology at University of California, San Diego and Rady Children’s Hospital, San Diego. “The novel delivery system supports the ability to deliver home phototherapy for chronic skin diseases in a user-friendly, effective method that should allow high adherence and compliance leading to positive patient outcomes.”

The Clarify System, cleared by FDA in 2017, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of care for the management of psoriasis and psoriatic arthritis. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress and satisfaction.

The Clarify smartphone app syncs to a patented, lightweight, handheld device which guides patients through delivering targeted narrowband UVB phototherapy treatments for their specific skin conditions. All treatment records, including photographs and patient-reported outcomes, are available to both the patient and the physician and can be used for evaluation during follow-up visits. Clarify CarePartners, trained patient support personnel, act as the first line of support for patients – coaching them on the use of the system and encouraging treatment adherence – greatly reducing the burden of these functions on the physician’s practice.

“This study supports what the scientific literature and clinical practice have demonstrated for decades – narrowband UVB phototherapy, as both monotherapy and as part of combination therapy regimens, is effective for the treatment of psoriasis,” said George Mahaffey, President & CEO of Clarify Medical. “The Clarify System’s patented technology and patient support function enables patients to administer treatment at home with the same level of control and care that they would receive in the clinic. We are excited to provide this novel targeted therapeutic option to patients managing psoriasis, vitiligo and other chronic skin conditions.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.